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This study investigated the use of microencapsulated bile salt hydrolase (BSH) overproducing Lactobacillus plantarum 80 cells for
oral delivery applications using a dynamic computer-controlled model simulating the human gastrointestinal (GI) tract. Bile salt
deconjugation rates for microencapsulated BSH overproducing cells were 4.87 ± 0.28μmol/g microcapsule/h towards glycocon-
jugates and 0.79 ± 0.15μmol/g microcapsule/h towards tauroconjugates in the simulated intestine, a signiﬁcant (P<.05) increase
over microencapsulated wild-type cells. Microcapsules protected the encased cells in the simulated stomach prior to intestinal
release, maintaining cell viability above 109 cfu/mL at pH 2.5 and 3.0 and above 106 cfu/mL at pH 2.0 after 2-hour residence times.
In the simulated intestine, encased cell viability was maintained above 1010 cfu/mL after 3, 6, and 12-hour residence times in bile
concentrations up to 1.0%. Results show that microencapsulation has potential in the oral delivery of live BSH active bacterial
cells. However, in vivo testing is required.
Copyright © 2007 Christopher Martoni et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The genus lactobacillus is currently the focus of much sci-
entiﬁc and commercial interest due to a myriad of health-
promoting eﬀects in the gastrointestinal tract (GI) [1, 2]. In
recent years, various lactobacilli strains have proven to lower
total or low-density lipoprotein cholesterol (LDL-C) in hu-
mans [3, 4] and animals [5, 6]. This eﬀect can at least par-
tiallybeattributedtotheassimilationofcholesterolbybacte-
rial cells and the enzymatic deconjugation of bile salts [5, 7].
Bilesalthydrolase(BSH),theenzymeresponsibleforbilesalt
deconjugationintheintestine,hasbeendetectedandcharac-
terized in several intestinal lactobacillus species [8–10]. Fur-
thermore, increasing bile salt deconjugation in the intesti-
nal lumen through oral delivery of lactobacilli has garnered
attention in recent years [8, 11–13]. It has also been sug-
gested that BSH activity is a requirement in the selection of
cholesterol lowering microorganisms, as nondeconjugating
organisms do not appear to have any signiﬁcant cholesterol
removal ability in culture medium [14]. However, insuﬃ-
cient survival when passing from the mouth to the intestine
has limited the potential of many probiotics from clinical or
commercial use [15, 16].
Artiﬁcial cell microencapsulation, a concept in which bi-
ologically active materials are encapsulated in specialized ul-
trathin semipermeable polymer membranes, has been pro-
posed as a means to improve cell viability in the GI [17–
20]. Earlier studies show that microencapsulated BSH over-
producing Lactobacillus plantarum 80 cells has potential in
oral delivery applications [21]. However, no study has de-
termined its actual utility and functionality in oral admin-
istration. In this research, towards the goal of oral delivery
applications, we investigate the potentials of microencapsu-
lated live BSH active cells in a computer-controlled dynamic
human GI model. The computer-controlled GI model sim-
ulates the complex GI environment at each stage of transit.2 Journal of Biomedicine and Biotechnology
Speciﬁcally, the apparatus, consisting of ﬁve bioreactor ves-
sels arranged in series, mimics the gradual transit of ingested
food products and therapeutics through the human digestive
tract in which in vivo conditions with regard to pH, temper-
ature, bacteria, enzyme types and activities, volume, agita-
tion, and food particles are closely simulated. Investigation
of oral formulations in the GI environment is crucial before
furthertestinginanimalmodelstounderstandthepotentials
and limitations of delivery formulations. With this aim, the
current study therefore investigates the performance of mi-
croencapsulated BSH active lactobacillus in the simulated GI
tract.
2. MATERIALS AND METHODS
2.1. Mediaandchemicals
Lactobacilli de Man, Rogosa, Sharpe (MRS) broth and agar
were obtained from Fisher Scientiﬁc (Fair Lawn, NJ, USA).
Alginate (low-viscosity) and poly-L-lysine (hydrobromide,
MW 21,320) were obtained from Sigma (Saint Louis, Mo,
USA).Thesodiumsaltsofglycocholicacid,taurodeoxycholic
acid,andglycodeoxycholicacidandmethanol(HPLC-grade)
were obtained from Sigma. Sodium acetate was purchased
from Fisher Scientiﬁc. All food composition materials were
purchased from Sigma; pancreatin was obtained from Acros;
and oxgall was obtained from Difco. Unless otherwise speci-
ﬁed, all other chemicals were of analytical grade and not pu-
riﬁed any further prior to use.
2.2. Bacteriaandcultureconditions
The bacterial strains used in this study were L. plantarum 80
BSH overproducing strain (BSH+)a n dL. plantarum 80 wild
type (wt). L. plantarum 80 BSH+ carries the multicopy plas-
mid pCBH1 containing the L. plantarum 80 chromosomal
BSHgeneandanerythromycinresistancegene.Overproduc-
tion of the BSH enzyme in L. plantarum 80 BSH+ was ob-
tained as described by Christiaens et al. [11]. Stock cultures
of both strains were stored in 50% glycerol at −80◦C. The
bacteria were cultivated in sterile de Man, Rogosa, Sharpe
(MRS) broth (1% inoculum) at 37◦C for 20 hours. Ery-
thromycin was supplemented (100μg/mL) for plasmid selec-
tion. Prior to experimental use, three subcultures were per-
formed in the appropriate medium.
2.3. PreparationofAPAmicrocapsulescontaining
L.plantarum80strains
Alginate-poly-L-lysine-alginate (APA) microcapsules con-
taining L. plantarum 80 BSH+ c e l l sw e r ep r e p a r e da sf o l l o w s .
Growncultureswereisolatedafter20hoursbycentrifugation
at 8000g for 15 minutes at 15◦C. The cell isolates were sus-
pended in sterile saline (0.85% NaCl) and slowly added to a
gently stirred 1.5%(w/v) sodium alginate solution. In a ster-
ile environment, the bacterial alginate suspension was passed
through an Inotech Encapsulator IER-20 (Inotech Biosys-
tems International Inc., Rockville, Md, USA) with an inter-
nal nozzle diameter of 300μm. After extrusion, the droplets
were allowed to gel for 5 minutes in a gently stirred ster-
ile 0.1M CaCl2 solution. The Ca-alginate beads were coated
with 0.1%(w/v) poly-L-lysine and 0.1%(w/v) Na-alginate
for 10 minutes and 5 minutes, respectively. Microcapsules
were washed in sterile saline between each coat and after the
encapsulation procedure. Microcapsules containing L. plan-
tarum 80 wild-type and empty microcapsules (control) were
prepared as above. All batches of microcapsules were stored
in minimal solution (90% saline, 10% MRS broth) at 4◦C.
2.4. InvestigationofBSHactivityofmicrocapsulesin
simulatedGImodel
BSH activity was measured in real time utilizing a sim-
ulated human GI model (Figure 1) consisting of vessels
representing the stomach, small intestine, ascending colon,
transverse colon, and descending colon. Microcapsules con-
taining L. plantarum 80 BSH+ cells were ﬁrst exposed to
the stomach compartment consisting of a food suspension
adjusted to pH 2.0 at 37◦Ca n d1 0 0 R P Ma g i t a t i o n .T h e
food component contained starch 3.0g/L; pectin 2.0g/L;
mucin 4.0g/L; arabinogalactan 1.0g/L; xylan 1.0g/L; yeast
extract 3.0g/L; peptone 1.0g/L; glucose 0.4g/L, and cysteine
0.5g/L. After 1 hour, microcapsules were transferred to the
small intestine compartment consisting of the acidiﬁed food
suspension readjusted to pH 6.5 and supplemented with
5 m Mg l y c o d e o x y c h o l i ca c i d( G D C A ) ,5 m Mt a u r o d e o x y -
cholic acid (TDCA), pancreatin 0.18g/L, and sodium bicar-
bonate 2.4g/L. The total bile salt concentration was approxi-
mately0.5%(w/v).Microcapsuleswereincubatedinthesim-
ulated small intestine for 10 hours. Supernatant was sampled
at intervals of 1 hour and processed to determine bile salt
concentrations in the reaction vessels. Viable cell count was
monitored pre-stomach exposure, pre-small intestine expo-
sure, and post-small intestine exposure. Microcapsules con-
taining L. plantarum 80 wild type were tested as above and
empty microcapsules were used as controls. Microcapsules
were visualized microscopically to determine the eﬀect of
simulatedGItransitonmicrocapsuleintegrity.Theunpaired
student t-test was used to determine which means diﬀered
signiﬁcantly (P < .05).
2.5. AnalysisofbilesaltconcentrationsusingHPLC
Supernatant samples were prepared for HPLC analysis using
the procedure described by Jones et al. [21]with some modi-
ﬁcations. Brieﬂy, 250μl samples were acidiﬁed with 2.5μlo f
6N HCl and supplemented with 250μl of Methanol contain-
ing 4mM glycocholic acid (GCA) as internal standard. The
samples were vortexed, shaken at 225RPM for 10 minutes,
and centrifuged at 1000g for 20 minutes at 10◦C. The su-
pernatant was ﬁltered through a 0.22μmP V D F4ﬁ l t e r( M i l -
lipore) and analyzed directly. Standards for calibration con-
taining 0, 1, 2, 3, 4, 5, 6mM GDCA and TDCA were treated
as above.
A modiﬁcation of the HPLC procedures described by
Scalia [22] was used to determine bile salt concentrations.
A n a l y s e sw e r ep e r f o r m e do nar e v e r s e - p h a s eC - 1 8c o l -
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Figure 1: Computer-controlled dynamic human GI model. Bioreactors in series representing stomach (Vessel 1), small intestine (Vessel 2),
ascending colon (Vessel 3), transverse colon (Vessel 4), and descending colon (Vessel 5).
H i C h r o m( N o v a t o ,C a l i f ,U S A ) .T h es o l v e n t su s e dw e r e
.05M sodium acetate buﬀer adjusted to pH 4.3 with o-
phosphoric acid and ﬁltered through a 0.22μm ﬁlter (Nal-
gene) (Solvent A) and HPLC-grade Methanol (Solvent B).
Anisocraticelutionwasapplied,consistingof30percentSol-
vent A and 70 percent Solvent B at a ﬂow rate of 1.0 mL/min.
An injection loop of 20μl was used and sample detection oc-
curred at 210nm.
2.6. SurvivalofmicroencapsulatedL.plantarum80
BSH+ insimulatedstomach
G a s t r i cs u rv i v a lo fm i c r o e n c a p s u l a t e dL. plantarum 80 BSH+
cellswasexaminedbyexposingthemicrocapsulestothesim-
ulated stomach compartment of the simulated human GI
model adjusted to pH 1.5, 2.0, 2.5, and 3.0 with 1.0M HCl.
Incubation was performed at 37◦C and 100RPM agitation
for 4 hours. For viability studies, aliquots were removed af-
ter 0, 30, 60, 90, 120, and 240 minutes. At each time point,
microcapsules were mechanically ruptured to release the en-
cased bacteria and serial dilutions were performed. Aliquots
were plated on MRS agar, and the plates were incubated at
37◦C for 72 hours.
2.7. SurvivalofmicroencapsulatedL.plantarum80
BSH+ insimulatedsmallintestine
Small intestinal survival of microencapsulated L. plantarum
80 BSH+ cells was measured by exposing the microcapsules
to the small intestine compartment of the simulated hu-
man GI model. The eﬀect of bile concentration on viabil-
ity was measured by supplementing oxgall at concentrations
of 0, 0.25, 0.5, and 1.0%. Pancreatin and sodium bicarbon-
ate were supplemented at physiological levels of 0.18g/L and
2.4g/L, respectively. Incubation was performed at 37◦Ca n d
100RPM agitation for 72 hours. Cell viability studies were
performed after 0, 3, 6, 12, 24, 36, 48, and 72 hours. As
mentioned above, aliquots were plated on MRS agar, and the
plates were incubated at 37◦C for 72 hours.
3. RESULTS
3.1. MicroencapsulationofL.plantarum
80BSH+ strains
APA microcapsules containing L. plantarum 80 cells were
prepared using optimized encapsulation procedures. 5g of
bacterial cell isolate were used per 100g of microcapsules, re-
sulting in a bacterial enumeration of at least 109 cfu/mL mi-
crocapsule. No signiﬁcant diﬀerences in size (P > .05) were
noted between empty APA microcapsules and L. plantarum
80 loaded APA microcapsules. The resultant diameter of all
batches of APA microcapsules was 608 ± 36μm.
3.2. Bilesalthydrolyzingactivityof
microencapsulatedL.plantarum80BSH+
strainsinsimulatedGImodel
APA microcapsules containing L. plantarum 80 strains were
exposed to stomach conditions for 60 minutes prior to in-
testinal conditions for 10 hours. Figure 2 shows bile salt
deconjugation of taurodeoxycholic acid (TDCA) and gly-
codeoxycholic acid (GDCA) over time by gastric stressed
Lp80 BSH+ microcapsules in comparison with Lp80 wild
type microcapsules. Lp80 BSH+ microcapsules deconjugated
both GDCA and TDCA at a signiﬁcantly greater rate (P <
.05) than Lp80 wild type microcapsules. Furthermore, both
encapsulated Lp80 strains showed a preference for GDCA
over TDCA (P < .05). As seen in Figure 3, the average BSH
activity towards glycoconjugates as a function of time was
4.87 ± 0.28μmol/g microcapsule/h for Lp80 BSH+ micro-
capsules and 0.65 ± 0.12μmol/g microcapsule/h for Lp80
wild type microcapsules. Towards tauroconjugates, the aver-
age BSH activity over time was 0.79 ± 0.15μmol/g micro-
capsule/h for Lp80 BSH+ microcapsules and 0.35 ±.07μmol4 Journal of Biomedicine and Biotechnology
Table 1: Survival of microencapsulated L. plantarum 80 wild-type
(control) cells and microencapsulated L. plantarum 80 BSH+ (test)
cells after simulated stomach (60 minutes) and intestinal (10 hours)
transit during bile salt hydrolase assay.
Viable cell count [log (cfu/ml)]
Lp80wt (Control) Lp80 BSH+ (Test)
Pre-stomach transit 9.47 ±0.18 9.40 ±0.11
Post-stomach transit 7.88 ±0.38 8.01 ±0.27
Post-stomach and intestinal
transit
8.75 ±0.46 8.86 ±0.41
DCA/g microcapsule/h for Lp80 wild type microcapsules.
Lp80 BSH+ microcapsules exhausted the entire GDCA con-
tent within 6 hours. Maximal activity was reached in the
second and third hours, with deconjugation rates of 7.53
and 9.24μmol DCA liberated/g microcapsule/h, respectively.
There was no signiﬁcant increase in BSH activity towards
TDCA after GDCA was completely displaced in the medium.
Simulated stomach exposure at pH 2.0 for 60 minutes
resulted in a viability decrease of 1.39logcfu/mL for mi-
croencapsulated L. plantarum 80 BSH+ and 1.59log cfu/mL
for microencapsulated L. plantarum 80 wild type (Table 1).
There were no signiﬁcant diﬀerences (P > .05) between
strains prior to release into the intestine, with both batches
of microcapsules maintaining viability at approximately
108 cfu/mL. The alginate microcapsule core shrank signiﬁ-
cantly (P < .05) in gastric conditions, decreasing from 608 ±
36μm to 544 ± 40μm( Figure 5). However, mechanical sta-
bility remained intact at pH 2.0 and there was no signiﬁcant
release of bacteria into the surrounding medium (data not
shown).
Simulated intestinal exposure for a 10-hour period re-
sulted in a viability increase of 0.9–1.0logcfu/mL, with
no signiﬁcant diﬀerences between microencapsulated strains
(Table 1). APA microcapsules swelled in the simulated small
intestine, with diameter increasing signiﬁcantly (P < .05)
from 544 ± 40μm post-gastric exposure to 725 ± 55μm
post-intestinal exposure. Both microencapsulated strains
lowered batch pH of intestinal contents after 10-hour incu-
bation in comparison to control, with Lp80 BSH+ microcap-
sules having a signiﬁcantly greater eﬀect than Lp80 wild type
microcapsules (Figure 4).
3.3. ToleranceofmicroencapsulatedLp80BSH+ cells
tosimulatedstomachconditions
Microcapsules containing Lp80 BSH+ cells were investigated
for survival in stomach conditions in the simulated human
GI model at pH 1.5, 2.0, 2.5, and 3.0 at 37◦C and 100RPM
agitation. In all experiments, pH variation in the medium
due to the incubation of microencapsulated live cells was less
than 10% during the 4-hour period. Figure 6 shows virtually
no loss of cell viability during the estimated stomach resi-
d e n c et i m ea tp H2 . 5a n d3 . 0 .A tp H3 . 0 ,c e l lv i a b i l i t yw a sr e -
tained over the ﬁrst 90 minutes and then decreased slightly,
resulting in a total cell loss of approximately 0.6logcfu/mL
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Figure 2: Bile acid deconjugation by microencapsulated L. plan-
tarum 80 wild type (control) cells and microencapsulated L. plan-
tarum 80 BSH+ (test) cells in simulated intestine following 60-
minute exposure time in simulated stomach. Overlaid HPLC chro-
matograms showing decreasing TDCA and GDCA concentrations
over time by microencapsulated (a) Lp80 wild type cells and (b)
Lp80 BSH+ cells. (c) Graphical comparison of control and test mi-
crocapsules. GCA was used as internal standard.Christopher Martoni et al. 5
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Figure 4: Eﬀect of empty microcapsules, microencapsulated L.
plantarum 80 wild type (control) cells, and microencapsulated L.
plantarum 80 BSH+ (test) cells on simulated intestine pH.
after 4 hours. At pH 2.5, microencapsulated cells showed a
gradual loss of viability during the ﬁrst 90 minutes in con-
trast to pH 3.0. This was followed by a leveling oﬀ eﬀect re-
sulting in a total cell loss of approximately 1.09log cfu/mL
after4hours.AtpH2.0,viabilitydecreasedlinearlyovertime
with total cell loss of 0.58, 2.13, 2.63, and 3.64logcfu/mL af-
ter 30, 60, 90, and 120 minutes, respectively. In simulated
stomach conditions at pH 1.5, microencapsulated cells were
not viable after 30-minute exposure time.
3.4. AdaptiveresponseofmicroencapsulatedLp80
BSH+ tobilestressinsimulatedsmallintestine
Microcapsules containing Lp80 BSH+ cells were investigated
for survival in simulated intestinal juices in the presence of
physiologicalconcentrationsofpancreatin(0.18g/L)andox-
gall (0%, 0.25%, 0.50%, and 1.0%w/v) for 72 hours. The
initial pH of all solutions was in the range of 7.4 to 7.6. At
all concentrations, APA microcapsules remained intact and
cells were retained for up to 72 hours with 100RPM agita-
tion. As seen in Figure 8, encapsulated cells showed signif-
icant increases in viability over the ﬁrst 3-, 6-, and 12-hour
periodsintheabsenceofbileandatbileconcentrationsinin-
termediate physiological range of 0.25%w/v. In contrast, cell
number was retained but not increased at high-oxgall con-
centrations of 0.50% and 1.0%w/v after 12 hours. Over the
subsequent 12 hours, a drop in cell number was observed
at all concentrations; however, the cell viability at 0% and
0.25%w/v batches were still above initial levels.
Figure 8 shows change in pH over time at diﬀerent oxgall
concentrations. In solutions containing no oxgall, a pH min-
imum of approximately 4.5 was reached after 12 hours and
was subsequently retained for the remainder of the experi-
ment. With oxgall present in solution, it required a longer
time for pH to reach its minimal level. This level was sub-
sequently retained for the remainder of the experiment. The
ﬁnal pH in each ﬂask increased with increasing oxgall con-
centration.
4. DISCUSSION
The current study investigated the use of microencapsu-
lated bile salt hydrolase overproducing Lactobacillus plan-
tarum 80 cells for oral delivery applications using a dynamic
computer-controlled model simulating the human gastroin-
testinal tract. The microcapsules were found to be adept
at protecting the encased cells at less acidic stomach con-
ditions of pH 2.5 and 3.0 with cell viabilities remaining
above 109 cfu/mL after a 4-hour residence time in the sim-
ulated stomach (Figure 6) .T h eo r a lp o t e n t i a lo fl a c t o b a c i l l i
is directly related to their ability to produce acid and ca-
pacity to function at low pH. In the average human, 2.5L
of gastric juice is secreted on a daily basis having a pH of
2–2.5 and a salt content of at least 0.5%w/v. Conditions
at pH 2.0 began to aﬀect microencapsulated cell survival
showing a linear decrease in viability over time. However,
even after 2 hours at pH 2.0, the microcapsules with sur-
viving viable entrapped cells satisﬁed the established crite-
rion of a minimum of 106 viable probiotic cells per mL fre-
quently cited to gain a therapeutic beneﬁt in the intestine
[23, 24]. In contrast, the threshold value was not reached
with nonencapsulated L. plantarum 80 cells which suﬀered
viability losses of 2.0logcfu/mL and 3.6logcfu/mL after 30
minutes and 60 minutes, respectively, at pH 2.0. Survival en-
hancements oﬀered by APA include the cross-linked mem-
brane providing physical barriers against the entry of harm-
ful components found in the GI tract. Furthermore, the al-
ginate core may oﬀer a buﬀering capacity thus limiting the
hostile eﬀect induced by the low pH in the stomach. At pH6 Journal of Biomedicine and Biotechnology
1.5, the retained cells showed signiﬁcant cell loss on account
of the loss of core cross-linking. Due to this harmful eﬀect at
pH 1.5, coupled with heightened survival at pH 2.5 indicates
that oral microcapsule therapy would be best accomplished
if ingested in a buﬀered system such as milk, yogurt, or milk-
based foodstuﬀs.
The inner alginate core was mildly susceptible to acid
hydrolysis at pH 2.0 in the simulated stomach, as seen in
Figure 5, which resulted in a 10% decrease in microcapsule
diameter. Alginates have been shown to undergo proton-
catalyzed hydrolysis dependent on factors such as pH, time,
and temperature [25]. Capsules remained stable, however,
with no signiﬁcant structural breakage. Microcapsules re-
leased into the small intestine after one-hour residence time
in the stomach experienced a time delay before reaching
maximal BSH activity (Figure 2). Re-establishment of cell
growth was found to coincide with BSH activity in the simu-
lated intestine. It has been previously shown for free L. plan-
tarum 80 cells that a correlation exists between growth and
BSH activity [12]. Although some studies indicate that the
optimal pH for bile salt deconjugation by lactobacilli is ap-
proximately 6.0 [26], others have suggested that the high
BSH activity of certain lactobacillus species during station-
ary phase is attributed to the low pH of the medium at this
stage [27]. In the current study, increases in BSH activity co-
incided with lowering pH due to the production of lactic
acid, however, the BSH activity of the encapsulated cells was
determined to be more a product of cell growth than of pH
conditions in the environment.
BSH activity of microencapsulated BSH overproducing
L. plantarum 80 cells was found to have a 5-fold preference
of glycodeconjugation over taurodeconjugation (Figure 3).
This compares with earlier studies showing BSH activity in
optimal MRS medium without initial gastric stress to have a
ratio of glycodeconjugation to taurodeconjugation of 2.5:1
[21]. This bears potential signiﬁcance in terms of in vivo
hypocholesterolemicactivity,sinceglycoconjugatesoutnum-
ber tauroconjugates in human bile with ratios as high as 9:1
in some individuals [28]. A myriad of data in the literature
suggests that substrates are predominantly recognized at the
amino acid moieties and most BSHs are more eﬃcient at
hydrolyzing glycoconjugates than tauroconjugates [29–31].
This is despite the fact that GDCA carries a higher toxic-
ity, which is magniﬁed at low pH [14]. The initial gastric
stress period therefore appeared to acclimatize the bacteria
to the low pH environment, therefore lessening the relative
toxicity to glycoconjugates in the intestine. In addition, there
wasasigniﬁcantdecreaseindeconjugationratetowardsboth
GDCA andTDCA in the simulated GI model ascompared to
optimal MRS media [21]. In comparing the two mediums,
simulated intestinal juices were found to be only moderately
more inhibitory to encapsulated cell viability and enzymatic
activity than MRS-bile media (data not shown), primarily
due to the addition of pancreatic enzymes into the medium.
The stress and viability losses imposed by gastric transit re-
sulted in an internal acidiﬁcation of the cells, which in turn
likely caused the reduction in activity of the acid sensitive
BSH enzyme.
Microcapsule swelling upon intestinal release (Figure 5)
resulted from among other factors, the aﬃnity of calcium
to phosphate in the medium and sodium/calcium exchange.
Swellingwasenhancedduetopre-treatmentinstomachcon-
ditions which resulted in slightly weaker core cross-linking.
However, over 90% of APA microcapsules maintained struc-
tural integrity through both stages of GI transit. The ma-
jority of BSH activity was therefore the direct result of re-
tained cells acting on conjugated bile salts diﬀusing through
the microcapsule membrane pores. Since large amounts of
deconjugated bile salts may have undesirable eﬀects for the
human host, concerns may arise over the safety of adminis-
tering a BSH-positive probiotic strain. However, it is likely
that the deconjugated products are precipitated at the low
pH values in the intestine caused by the fermentation prod-
ucts of lactic acid bacteria (Figure 4). Furthermore, this lo-
calized phenomenon is potentially increased within the mi-
crocapsule membrane, allowing for a greater precipitation of
deconjugation products which could then be bound and re-
tained within the microcapsule membrane and excreted with
the feces. In the current study, no environmental concentra-
tion of DCA was observed in the simulated intestine after 10
hours.
Resistance to bile toxicity is an important criteria used to
select for microencapsulation systems and probiotic strains
capable of performing eﬀectively in gastrointestinal environ-
ments. In a given day, 0.7L of pancreatic juice is secreted into
the proximal small intestine with a pH of 7.5–8.0 and a salt
content of at least 0.5%w/v. Daily bile acid secretions ap-
proach 20–30g/day sustaining an intestinal bile salt concen-
tration between 0.15 and 1.0% [32, 33]. According to Char-
teris et al., the majority of lactobacillus and biﬁdobacterium
strainsareintrinsicallyresistant tosimulated pancreatic juice
without the addition of bile salts [34]. In contrast, 31 of 47
lactobacillusstrainsexaminedbyJacobsenetal.wereseverely
inhibitedbybileanddidnotreplicateinbrothsupplemented
with 0.3% oxgall [35]. Furthermore, the protective capa-
bility oﬀered by BSH active bacteria in toxic bile environ-
m e n t si sn o ta l w a y se v i d e n t[ 36]. As seen in Figure 7,m i -
crocapsules containing L. plantarum 80 BSH+ cells exposed
to the simulated small intestine were shown to be highly re-
sistant to bile, either retaining or increasing viability after
3, 6, and 12-hour transit times at bile concentrations up to
1.0%w/v. It has been reported that survival at a bile con-
centration of 1000mg/L is considered optimal bile tolerance
for probiotic strains. It is therefore shown here that encap-
sulated strains do not lose viability after 12 hours in bile
concentrations at least 10 times the level proposed. While
high-oxgall concentrations of 0.5% and 1.0% were shown
to inhibit growth, encapsulated cells maintained initial via-
bility counts of 1010 cfu/mL during the ﬁrst 12 hours. Cell
metabolic activity was inhibited at higher concentrations of
oxgall as decrease in pH was more limited at higher concen-
trations. It could be concluded that production of lactic acid
was inhibited with increasing bile concentrations. Overall,
the protective eﬀect of microencapsulated BSH active bac-
teria in simulated intestinal transit was evident, particularly
at high-bile levels.Christopher Martoni et al. 7
(a) (b) (c)
Figure 5: Evaluation of microcapsule integrity and morphological
changes during simulated GI transit. (a) Pre-stomach transit. (b)
Post-stomach transit (60 minutes). (c) Post-stomach (60 minutes)
and intestinal (10-hour) transit. Microcapsule size (a) 608 ± 36μm
(b) 544 ± 40μm (c) 725 ± 55μm.
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Figure 6: Viability of microencapsulated L. plantarum 80 BSH+
cells in simulated stomach at pH 1.5, 2.0, 2.5, and 3.0, 37◦Ca n d
100RPM agitation.
5. CONCLUSIONS
Recent advances in metabolic engineering have enhanced the
enzymatic and immunomodulatory eﬀects of probiotics and
with time may provide more active therapeutic interven-
tion. For some time now, clinical and epidemiological evi-
dence have established a clear link between elevated serum
cholesterol and coronary artery disease (CAD) [37–39]. Lac-
tobacilli with active BSH are suggested to lower cholesterol
levels through an interaction with host bile salt metabolism
[8, 12]. The main proposed mechanism of cholesterol re-
duction involves an increased production of deconjugated
products in the intestine, thereby increasing the demand for
cholesterol as a precursor of bile salt synthesis. Furthermore,
deconjugated bile salts do not function as well as their con-
jugated counterparts in the solubilization of cholesterol and
therefore prevent it from being absorbed [40]. The preceding
studysuggeststhatmicrocapsulescontainingL.plantarum80
with enhanced BSH activity show excellent probiotic poten-
tialinthesimulatedGImodel.Thisstudyrepresentsaunique
biotechnological approach indicating that microencapsula-
tion maintains the enzymatic activity of BSH active bacte-
ria in the simulated GI transit while at the same time avoid-
ing the problems associated with the oral administration of
free bacterial cells. In addition to speciﬁc bile salt hydrolase
oral delivery applications, this study provides knowledge to-
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Figure 7: Adaptive response of microencapsulated L. plantarum 80
BSH+ cells to bile stress in simulated intestine at bile concentrations
of 0%, 0.25%, 0.50%, and 1.0%w/v, 37◦C, and 100RPM agitation.
Pancreatin (0.18g/L) and sodium bicarbonate (2.4g/L) concentra-
tions were kept constant.
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Figure 8: Eﬀect of bile concentration on metabolic activity of mi-
croencapsulated L. plantarum 80 BSH+ and change in pH in simu-
lated intestine. Triplicate samples were pooled prior to analysis.
wards the potential use of orally administered probiotic cells
for therapy.
While the potential of this approach is widespread, cur-
rent limitations must be addressed in order for this tech-
nology to be properly applied. Safety studies have indicated
that the use of genetically modiﬁed microorganisms pose no
greaterriskthantheoriginalunmodiﬁedproduct[41].How-
ever, there remain public and scientiﬁc concerns about the
safety of gene manipulation technology. One of the main
concerns is the possibility of repeated large doses of novel
microorganisms resulting in the transfer of genes to organ-
isms in the environment [42]. Consequently, even though
the encased cells are classiﬁed as nonpathogenic, regulatory
agencies may require exclusively no leaking of engineered
cells from ingested microcapsules into the host’s GI system.
Therefore, the design of an appropriate polymeric microcap-
sule membrane for such oral delivery applications is an im-
portant focus going forward.8 Journal of Biomedicine and Biotechnology
Additional research is required to substantiate these re-
sults; in particular in vivo studies demonstrating the link be-
tween increased bile salt deconjugation and cholesterol re-
duction using microcapsules. Important considerations for
in vivo studies may include dosage, frequency, and timing
of therapeutic administration, composition of microcapsule
membrane, and potential side eﬀects of byproducts. While
these factors present challenges, we believe that the potential
of this approach is to carry heightened beneﬁt while mini-
mizing risk.
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